ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1621

T Helper 17 Cells and Interferon Type I: Partners In Crime In SLE?

Odilia B.J. Corneth1, Zana Brkic2, Cornelia G. van Helden-Meeuwsen3, Radboud J.E.M. Dolhain4, Naomi I. Maria3, Sandra M.J. Paulissen4, Nadine Davelaar5, Jan Piet van Hamburg5, Paul L. Van Daele3, Virgil A. Dalm2, Martin van Hagen3, Marjan A. Versnel2 and Erik Lubberts6, 1Rheumatology and Immunology, Erasmus Medical Center, Rotterdam, Netherlands, 2Erasmus Medical Center, Immunology, Rotterdam, Netherlands, 3Immunology, Erasmus Medical Center, Rotterdam, Netherlands, 4Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, 5Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 6Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Auto-immunity, cytokines and interferons, SLE, T cells

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus-Human Etiology and Pathogenesis: Genetics and Genomics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

A hallmark of systemic autoimmune diseases, such as systemic lupus erythematotsus (SLE), is the increased expression of interferon (IFN) type I inducible genes, the so-called IFN type I signature. Recently, a novel T helper 17 subset (Th17 cells), which produces IL-17A, IL-17F, and IL-22, has also been implicated in autoimmune diseases. We investigated a possible link between these two pro-inflammatory immune pathways in SLE.

Methods:

25 SLE patients and 15 healthy controls (HC) were included. SLE patients were divided into an IFN type I signature negative (n=9) and positive (n=16) group as assessed by mRNA expression of IFN type I inducible genes. Peripheral expression of Th17 cytokines IL-17A, IL-17F and IL-22 by CD4+CCR6+ memory T cells was measured by flow cytometry and compared between IFN type I signature positive and negative patients and HC.

Results:

Increased fraction of IL-17A and IL-17A/IL-17F double producing CCR6+ cells was found in IFN type I positive patients compared with IFN type I negative patients and HC. The expression of IL-17A and IL-17F within CCR6+ cells correlated significantly with IFN scores. In addition, we found a significant correlation between BAFF and IL-21 producing CCR6+ cells.

Conclusion:

Here we show for the first time a correlation between IFN type I activation and expression of the Th17 cytokines in SLE patients. These data give new insight into the pathogenesis of SLE with possible implications for treatment.


Disclosure:

O. B. J. Corneth,
None;

Z. Brkic,
None;

C. G. van Helden-Meeuwsen,
None;

R. J. E. M. Dolhain,
None;

N. I. Maria,
None;

S. M. J. Paulissen,
None;

N. Davelaar,
None;

J. P. van Hamburg,
None;

P. L. Van Daele,
None;

V. A. Dalm,
None;

M. van Hagen,
None;

M. A. Versnel,
None;

E. Lubberts,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/t-helper-17-cells-and-interferon-type-i-partners-in-crime-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology